Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma

Nuclear Medicine Communications

Volumn 29, Issue 7, 2008, Pages 636-641

  Zuijdwijk, Marc D ^a   Vogel, Wouter V ^a   Corstens, Frans H M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FDG PET; Fluorodeoxyglucose PET; Patient management; Radioiodine; Thyroglobulin; Thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; ONCOCYTOMA; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT PLANNING; BLOOD; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; THYROID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 49649083369     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f813e1     Document Type: Article

References (41)

1. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48:221-226.
2. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47:616-624.
3. Choi MY, Chung JK, Lee HY, So Y, Park do J, Jeong JM, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 2006; 20:547-552.
4. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001; 42:1464-1469.
5. Iagaru A, Masamed R, Singer PA, Conti PS. 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol 2006; 8:309-314.
6. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26:1547-1552.
7. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
8. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37:1468-1472.
9. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115:237-243.
10. Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, et al. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31:491-498.
11. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42:71-76.
12. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 2006; 47:1260-1266.
13. Alzahrani AS, Mohamed GE, Al Rifai A, Al-Sugair A, Abdel Salam SA, Sulaiman OM, Demirkaya O. Role of [18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006; 12:152-158.
14. Goshen E, Cohen O, Rotenberg G, Oksman Y, Karasik A, Zwas ST. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 2003; 24:959-961.
15. Wu YJ, Wu HS, Yen RF, Shen YY, Kao CH. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography. Anticancer Res 2003; 23(3C):2973-2976.
16. 131I whole body scan. Endocr Res 2003; 29:169-175.
17. Plotkin M, Hautzel H, Krause BJ, Schmidt D, Larisch R, Mottaghy FM, et al. Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid 2002; 12:155-161.
18. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 2000; 179:457-461.
19. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999; 9:797-804.
20. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40:986-992.
21. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998; 383:160-163.
22. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun 1998; 19:547-554.
23. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001; 234:804-811.
24. 131I scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001; 23:94-103.
25. Sarlis NJ, Gourgiotis L, Guthrie LC, Galen B, Skarulis MC, Shawker TH, et al. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med 2003; 28:208-217.
26. Grunwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997; 7:327-335.
27. Grunwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23:312-319.
28. Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42:414-419.
29. 131I whole body scan. Anticancer Res 2003; 23(5b):4235-4238.
30. Lowe VJ, Mullan BP, Hay ID, McIver B, Kasperbauer JL. 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med 2003; 44:1402-1406.
31. Chen YK, Liu FY, Yen RF, Kao CH. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol 2003; 10:835-839.
32. Deichen JT, Schmidt C, Prante O, Maschauer S, Papadopoulos T, Kuwert T. Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro. Eur J Nucl Med Mol Imaging 2004; 31:507-512.
33. Van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EG, Dullaart RP. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002; 12:381-387.
34. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000; 41:1989-1995.
35. Saab G, Driedger AA, Pavlosky W, McDonald T, Wong CY, Yoo J, Urbain JL. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006; 16:267-272.
36. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:91-95.
37. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:641-647.
38. Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, Lind P. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007; 34:487-495.
39. Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006; 60:409-413.
40. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006; 36:194-205.
41. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41:1010-1015.